The association of robotic surgical technology and hospital prostatectomy volumes: Increasing market share through the adoption of technology

Cancer

Volumn 118, Issue 2, 2012, Pages 371-377

  Neuner, Joan M ^a   See, William A ^a   Pezzin, Liliana E ^a   Tarima, Sergey ^a   Nattinger, Ann B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Device approval; Legislation and jurisprudence; Physician's practice patterns trends; Prostate cancer; Prostatic neoplasms surgery; Prostatic neoplasms therapy

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CENTRALIZATION; HEALTH CARE UTILIZATION; HOSPITAL SERVICE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATECTOMY SURGICAL VOLUME; ROBOTICS; SURGICAL TECHNOLOGY; UNITED STATES;

BIOMEDICAL TECHNOLOGY; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROBOTICS; SURGERY DEPARTMENT, HOSPITAL; TREATMENT OUTCOME; WISCONSIN;

EID: 84855483445     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26271     Document Type: Article

References (35)

1. Pauly MV. Competition and new technology. Health Aff (Millwood). 2005; 24:1523-1535.
2. Steiner CA, Bass EB, Talamini MA, Pitt HA, Steinberg EP. Surgical rates and operative mortality for open and laparoscopic cholecystectomy in Maryland. N Engl J Med. 1994; 330:304-308.
3. Escarce JJ, Bloom BS, Hillman AL, Shea JA, Schwartz JS. Diffusion of laparoscopic cholecystectomy among general surgeons in the United States. Med Care. 1995; 33:256-271.
4. Kolata G. Results unproven, robotic surgery wins converts. New York Times. February 14, 2010:A1.
5. Leonhardt D. Economic scene: in health reform, a cancer offers an acid test. New York Times. July 7, 2009:A14.
6. Ficarra V, Cavalleri S, Novara G, Aragona M, Artibani W. Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review. Eur Urol. 2007;51:45-56. (Pubitemid 44821522)
7. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: the comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008; 48:435-448. (Pubitemid 351665443)
8. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009; 302:1557-1564.
9. Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol. 2008; 26:2278-2284.
10. Barbash GI, Glied SA. New technology and health care costs - the case of robot-assisted surgery. N Engl J Med. 2010; 363:701-704.
11. Nguyen PL, Lipsitz SR, Choueiri TK, et al. Time trends in the utilization of higher-cost treatments for prostate cancer: 2002-2007 [abstract]. Paper presented at: ASCO 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, Calif. Abstract 18.
12. Wennberg JE, Birkmeyer JD, eds. The Dartmouth Atlas of Cardiovascular Health Care. Chicago, IL: American Hospital Association Press;1999.
13. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006; 98:973-978. (Pubitemid 44536442)
14. Hudak BB, O'Donnell J, Mazyrka N. Infant sleep position: pediatricians' advice to parents. Pediatrics. 1995; 95:55-58.
15. Weinstein JN, Lurie JD, Olson PR, Bronner K, Fisher ES. United States trends and regional variations in lumbar spine surgery: 1992- 2003. Spine. 2006; 31:2707-2714. (Pubitemid 44679601)
16. Wisconsin Department of Health Services, Division of Public Health, Office of Health Informatics. Wisconsin Cancer Incidence and Mortality, 2002-2006 (P-45328-06). Madison, WI: Wisconsin Department of Health Services, Division of Public Health;2009.
17. Barocas DA, Salem S, Kordan Y, et al. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence- free survival. J Urol. 2010; 183:990-996.
18. Vickers AJ, Bianco FJ, Serio AM, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007; 99:1171-1177. (Pubitemid 47233067)
19. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002; 346:1138-1144. (Pubitemid 34984605)
20. Weizer AZ, Ye Z, Hollingsworth JM, et al. Adoption of new technology and healthcare quality: surgical margins after robotic prostatectomy. Urology. 2007; 70:96-100. (Pubitemid 47081089)
21. Scales JCD, Jones PJ, Eisenstein EL, Preminger GM, Albala DM. Local cost structures and the economics of robot assisted radical prostatectomy. J Urol. 2005; 174:2323-2329. (Pubitemid 41611814)
22. Mitka M. Direct-to-consumer advertising of medical devices under scrutiny. JAMA. 2008; 300:1985-1986.
23. Chernew ME, Jacobson PD, Hofer TP, Aaronson KD, Fendrick AM. Barriers to constraining health care cost growth. Health Aff (Millwood). 2004; 23:122-128. (Pubitemid 39531458)
24. Luft HS, Robinson JC, Garnick DW, Maerki SC, McPhee SJ. The role of specialized clinical services in competition among hospitals. Inquiry. 1986; 23:83-94.
25. Centers for Medicare and Medicaid Services. Decision memo for computed tomographic angiography (CAG-00385N). http://www.cms.hhs. gov/mcd/ viewdecisionmemo.asp?id=206. Accessed March 12, 2008.
26. Tversky A, Kahneman D. Advances in prospect theory: cumulative representation of uncertainty. J Risk Uncertainty. 1992; 5:297-323.
27. United States Congress. Food and Drug Administration Modernization Act of 1997. Public Law 105-115 (111 Stat 2295). Washington, DC: US Government Printing Office; 1997.
28. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009; 302:2679-2685.
29. Kramer DB, Mallis E, Zuckerman BD, Zimmerman BA, Maisel WH. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Am J Ther. 2010; 17:2-7.
30. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010; 102:950-958.
31. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302:1202-1209.
32. Makarov DV, Yu JB, Desai RA, Penson DF, Gross CP. The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care. 2011; 49:333-339.
33. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29:1517-1524.
34. Pearson SD, Bach PB. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff. 2010; 29:1796-1804.
35. Vanderbilt University. Vanderbilt wins CHOICE award for prostate cancer research. http://www.mc.vanderbilt.edu/news/releases.php?release=1896. Accessed December 6, 2010.